Muciclar (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Muciclar, is a mucolytic agent presented as an oral formulation for oral use. It helps reduce mucus viscosity and is used in conditions with excessive respiratory secretions. GNH USA supplies Muciclar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ambroxol Hydrochloride is a mucolytic that acts on respiratory conditions characterized by thickened secretions.

Acute bronchitis: improves clearance of mucus and eases cough. Chronic bronchitis: reduces mucus viscosity to facilitate expectoration. Respiratory tract infections with mucus hypersecretion: enhances mucociliary transport and relieves congestion.

Ambroxol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Altered taste sensation (metallic or bitter). - Nausea or mild gastrointestinal discomfort. - Diarrhea or loose stools. - Headache. - Skin rash or pruritus.

Serious or Rare Side Effects: - Allergic reactions such as urticaria or angioedema. - Severe skin reactions (e.g., Stevens‑Johnson syndrome). - Hepatic dysfunction or elevated liver enzymes. - Eosinophilia or blood dyscrasias. - Anaphylactic shock (rare).

When using Ambroxol, consider the following precautions. - Liver function assessment: monitor hepatic enzymes in patients with pre‑existing liver disease. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Hypersensitivity: avoid in individuals with known allergy to ambroxol or related compounds. - Gastrointestinal tolerance: watch for persistent nausea or abdominal pain. - Pregnancy and lactation: safety data are limited; use only if benefit outweighs risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ambroxol may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Concurrent use with other mucolytic agents (e.g., N‑acetylcysteine) may increase risk of bronchospasm. - Co‑administration with anticholinergic drugs may diminish mucociliary clearance benefits.

Moderate Interactions (Monitor Closely): - Antacids may reduce oral absorption of ambroxol. - CYP2D6 inhibitors could raise plasma concentrations. - Warfarin therapy may experience altered anticoagulant effect. - Beta‑agonists may have additive bronchodilatory effects. - Cough suppressants may mask therapeutic cough, reducing clearance.